Advanced Robotic Telemedicine

InTouch Vita is a remote presence device component of a total acute care telemedicine solution and most advanced robotic device incorporating an array of intuitive, easy-to-use features that encourage physician adoption and clinical use. It was designed to increase efficiency with its AutoDrive capabilities that enable a remote medical provider to directly control or to automatically direct Vita to move to an intended location. 

InTouch Vita is cleared by the FDA for active patient monitoring that may be needed for taking immediate clinical action. Developed by InTouch Health and iRobot, the InTouch Vita can improve the independence of the remote clinician in managing patient care.

The VITA raises the bar for overseeing patient care remotely and allows doctors to proactively control a situation as if they were there.

An enhanced navigation capability that enables the VITA to better manage driving and navigation elements so the health care professional can put more focus on patient care tasks. State‐of‐the-art mapping and Obstacle Detection Obstacle Avoidance (ODOA) technologies allow safe, fast and highly flexible navigation in a clinical environment. This capability will allow a remote clinician or bedside nurse to send the VITA to a target destination with a single click, enabling a number of breakthrough clinical applications. A new, simple to use iPad user interface will enable quick and easy navigation to anywhere the VITA needs to go, as well as interaction with the patient, family and care team.

Real-time access to important clinical data, enabling a range of new workflow improvements for physicians, nurses and other patient care team members. For example, the VITA can be integrated with live patient data from the electronic medical record and is equipped with the ability to connect with diagnostic devices such as otoscopes and ultrasound. It comes equipped with the latest electronic stethoscope.

InTouch Health envisions that the expandable VITA platform will provide additional value in orchestrating team-wide care, as a clinical assistant to enhance efficiency and quality, and as a patient advocate to enhance the care experience.

Information on this page is provided for interest only on a "best efforts" basis and does not 
constitute personal advice. Always discuss medical conditions and related matters with your doctor.

Ref: http://www.intouchhealth.com/our-solutions/patient-access/intouch-vita/

Erectile Dysfunction Shock Wave Therapy (EDSWT)

Erectile Dysfunction Shock Wave Therapy (EDSWT) is an innovative approach to vasculogenic ED, delivered by Medispec’s ED1000, a device that uses advanced acoustics technology. This technology has proven to be effective in cardiology, with recent success in reversible ischemic tissues of the heart. EDSWT utilizes low-intensity extracorporeal shock waves, focusing on blood vessels and encouraging neovascularization in the penis shaft and crus. The low-intensity shock waves help relieve vascular deficiency, a common cause of erectile dysfunction.

By courtesy of Medispec

Proven effective in clinical testing, the ED1000 is a unique mobile system that performs the EDSWT protocol in a safe, efficient manner. Vasculogenic and diabetic ED patients, who are responsive to PDE5 inhibitors as well as those who are unresponsive, can receive shock wave therapy from the ED1000 and experience improved erectile functionality.

For the latter, which includes a substantial number of severe ED patients, the only solution to date are vacuum pumps, injections and perhaps implants. EDSWT therapy brings hope to those patients, by allowing more than 70% of them to become responsive to PDE5 inhibitors. As “end-stage” ED patients, they will be able to enjoy normal sexual functionality. With over 50% of men aged 40-70 suffering from ED, and even more from transient ED, Medispec’s breakthrough therapeutic system can bring lasting improvement in erectile function and new sexual spontaneity to millions – painlessly, naturally and safety.

Unlike conventional ED treatment, such as PDE5 inhibitors, EDSWT does not involve the use of any pharmaceuticals. Moreover, the shock wave treatment causes no side-effects or systemic load on other organs and healthy tissues. The non-invasive, painless EDSWT procedure is performed during a series of brief visits to the urology office, and requires no sedation or anesthesia. Discernable improvement in the erectile function of the penis can be visible within two weeks after therapy begins. 

Recent clinical studies revealed that patients reported a high rate of satisfaction for more than two years after treatment – all without reliance on PDE5 inhibitors. In clinical tests, EDSWT has shown significant long-term effectiveness. These results are confirmed by a double-blind placebo controlled study of a large group of patients.

 

Information on this page is provided for interest only on a "best efforts" basis and does not 
constitute personal advice. Always discuss medical conditions and related matters with your doctor.

Ref: http://medispec.com/solutions/erectile-disfunction/